Hadmuliv

Hadmuliv is an oral medication that combines the non‑steroidal anti‑inflammatory drug ibuprofen with the analgesic/antipyretic paracetamol. Marketed in the European Union, the product is formulated for systemic absorption after swallowing. By pairing two widely used pain‑relieving agents, Hadmuliv targets mild to moderate discomfort and fever while offering complementary mechanisms of action. It is generally intended for short‑term use in adults, though availability may vary by country.

Hadmuliv is indicated for the temporary relief of several common conditions that involve pain or elevated temperature.

- Mild to moderate musculoskeletal pain, such as backache or sprains. - Tension‑type headache and other primary headache disorders. - Fever associated with viral or bacterial infections. - Dental pain following procedures or toothache. - Post‑vaccination discomfort and low‑grade fever. - Menstrual cramps when additional analgesia is required.

The safety profile of Hadmuliv reflects the combined effects of ibuprofen and paracetamol, with most reactions being mild and reversible.

Common: - Nausea or mild stomach upset. - Indigestion or heartburn. - Transient headache. - Dizziness or light‑headedness. - Mild skin rash or itching.

Serious: - Gastrointestinal bleeding or ulcer perforation. - Elevated liver enzymes or hepatic injury. - Severe allergic reactions such as anaphylaxis. - Acute kidney injury, especially with dehydration. - Blood disorders like thrombocytopenia (rare).

Before using Hadmuliv, certain health considerations should be reviewed to minimize risk.

- Known hypersensitivity to ibuprofen, paracetamol, or other NSAIDs. - History of peptic ulcer disease or gastrointestinal bleeding. - Severe liver disease or markedly elevated liver enzymes. - Impaired renal function, chronic dehydration, or use of diuretics. - Pregnancy, particularly the third trimester, unless advised by a clinician. - Concurrent use of other NSAIDs or high‑dose paracetamol products. - Chronic alcohol consumption that may increase liver toxicity.

Hadmuliv can affect the activity of other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Other NSAIDs (e.g., aspirin, diclofenac) due to additive gastrointestinal risk. - Additional paracetamol‑containing products to prevent overdose.

Use with caution: - Anticoagulants such as warfarin, because ibuprofen may increase bleeding risk. - Antihypertensive agents (ACE inhibitors, diuretics, beta‑blockers) as NSAIDs can reduce their efficacy. - Lithium or methotrexate, where ibuprofen may raise serum concentrations. - Certain antidiabetic drugs, as NSAIDs can affect blood glucose control. - SSRIs or other serotonergic agents, which may increase bleeding tendency.